A phase I clinical trial evaluated a personalized neoantigen vaccine in high-risk renal cell carcinoma patients, demonstrating safety and ability to generate anti-tumor immune responses.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.